- Oops!Something went wrong.Please try again later.
Shares of Cellectis (NASDAQ:CLLS) were flatin after-market trading after the company reported Q4 results.
Earnings per share fell 20.55% year over year to ($0.88), which missed the estimate of ($0.78).
Revenue of $15,632,000 rose by 146.72% year over year, which beat the estimate of $7,640,000.
Cellectis hasn't issued any earnings guidance for the time being.
Cellectis hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Mar 04, 2021
Time: 08:00 AM
Recent Stock Performance
52-week high: $34.71
52-week low: $7.32
Price action over last quarter: Up 18.82%
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. The company reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.